Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

3903 ARTÍCULOS , VIENDO DEL 481 AL 495

Regulatory triangle of neurodegeneration, adult neurogenesis and microRNAs

Singh T, Jauhari A, Pandey A, Singh P, Pant AB, Parmar D, Yadav S.

CNS Neurol Disord Drug Targets. 2014 Feb;13(1):96-103. doi: 10.2174/18715273113126660190.

Insights on the neuromodulatory propensity of Selaginella (Sanjeevani) and its potential pharmacological applications

Chandran G, Muralidhara.

CNS Neurol Disord Drug Targets. 2014 Feb;13(1):82-95. doi: 10.2174/18715273113126660188.

Serotonin syndrome after the use of tramadol and ziprasidone in a patient with a deep brain stimulator for Parkinson disease

El-Okdi NS, Lumbrezer D, Karanovic D, Ghose A, Assaly R.

Am J Ther. 2014 Jul-Aug;21(4):e97-9. doi: 10.1097/MJT.0b013e3182456d88.

Animal models of Parkinson's disease: a gateway to therapeutics?

Le W, Sayana P, Jankovic J.

Neurotherapeutics. 2014 Jan;11(1):92-110. doi: 10.1007/s13311-013-0234-1.

Dual ligands targeting dopamine D2 and serotonin 5-HT1A receptors as new antipsychotical or anti-Parkinsonian agents

Ye N, Song Z, Zhang A.

Curr Med Chem. 2014;21(4):437-57. doi: 10.2174/09298673113206660300.

Novel approach to the role of NMDA receptors in traumatic brain injury

Shohami E, Biegon A.

CNS Neurol Disord Drug Targets. 2014;13(4):567-73. doi: 10.2174/18715273113126660196.

α-Synuclein ubiquitination and novel therapeutic targets for Parkinson's disease

Rott R, Szargel R, Shani V, Bisharat S, Engelender S.

CNS Neurol Disord Drug Targets. 2014;13(4):630-7. doi: 10.2174/18715273113126660195.

Retina measurements for diagnosis of Parkinson disease

Garcia-Martin E, Satue M, Otin S, Fuertes I, Alarcia R, Larrosa JM, Polo V, Pablo LE.

Retina. 2014 May;34(5):971-80. doi: 10.1097/IAE.0000000000000028.

Pharmacokinetics, safety and tolerability of rotigotine transdermal patch in healthy Japanese and Caucasian subjects

Cawello W, Kim SR, Braun M, Elshoff JP, Ikeda J, Funaki T.

Clin Drug Investig. 2014 Feb;34(2):95-105. doi: 10.1007/s40261-013-0150-5.

MRI reveals brain abnormalities in drug-naive Parkinson's disease

Planetta PJ, McFarland NR, Okun MS, Vaillancourt DE.

Exerc Sport Sci Rev. 2014 Jan;42(1):12-22. doi: 10.1249/JES.0000000000000003.

Cortical effects of deep brain stimulation: implications for pathogenesis and treatment of Parkinson disease

Li Q, Qian ZM, Arbuthnott GW, Ke Y, Yung WH.

JAMA Neurol. 2014 Jan;71(1):100-3. doi: 10.1001/jamaneurol.2013.4221.

Cognitive and motor function in long-duration PARKIN-associated Parkinson disease

Alcalay RN, Caccappolo E, Mejia-Santana H, Tang MX, Rosado L, Orbe Reilly M, Ruiz D, Louis ED, Comella CL, Nance MA, Bressman SB, Scott WK, Tanner CM, Mickel SF, Waters CH, Fahn S, Cote LJ, Frucht SJ, Ford B, Rezak M, Novak KE, Friedman JH, Pfeiffer RF, Marsh L, Hiner B, Payami H, Molho E, Factor SA, Nutt JG, Serrano C, Arroyo M, Ottman R, Pauciulo MW, Nichols WC, Clark LN, Marder KS.

JAMA Neurol. 2014 Jan;71(1):62-7. doi: 10.1001/jamaneurol.2013.4498.

Surgical treatment of Parkinson's disease: patients, targets, devices, and approaches

Wagle Shukla A, Okun MS.

Neurotherapeutics. 2014 Jan;11(1):47-59. doi: 10.1007/s13311-013-0235-0.

Long-term clinical outcome of fetal cell transplantation for Parkinson disease: two case reports

Kefalopoulou Z, Politis M, Piccini P, Mencacci N, Bhatia K, Jahanshahi M, Widner H, Rehncrona S, Brundin P, Björklund A, Lindvall O, Limousin P, Quinn N, Foltynie T.

JAMA Neurol. 2014 Jan;71(1):83-7. doi: 10.1001/jamaneurol.2013.4749.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias